Alexandra Bazeos
Welwyn Garden City, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.
Journal: BMC cancer
Published: September 02, 2021
Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Journal: Advances in therapy
Published: July 05, 2021
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Journal: American journal of hematology
Published: June 11, 2019
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 08, 2018
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Journal: Haematologica
Published: June 20, 2018
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.
Journal: Blood
Published: May 31, 2013
Biology of CML stem cells: the basis for clinical heterogeneity?
Journal: Leukemia supplements
Published: August 01, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026